A5070960398- Cardiac pacing and defibrillation studies
- Cardiac Arrhythmias and Treatments
- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac Imaging and Diagnostics
- Pharmacology and Obesity Treatment
- Lipoproteins and Cardiovascular Health
- Cardiomyopathy and Myosin Studies
- Atrial Fibrillation Management and Outcomes
- Advanced MRI Techniques and Applications
- Cardiovascular Syncope and Autonomic Disorders
- Cardiac Structural Anomalies and Repair
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cardiac electrophysiology and arrhythmias
- Acute Myocardial Infarction Research
- Cardiac Valve Diseases and Treatments
- COVID-19 Clinical Research Studies
- Lipid metabolism and disorders
- Cancer, Lipids, and Metabolism
- Cardiovascular Issues in Pregnancy
- Cardiovascular Effects of Exercise
- Pericarditis and Cardiac Tamponade
- Cardiovascular and exercise physiology
- Tracheal and airway disorders
- Adipokines, Inflammation, and Metabolic Diseases
Hellenic Red Cross
2023-2025
Red Cross Hospital
2025
King's College Hospital
2020-2024
Harefield Hospital
2021-2023
Guy's and St Thomas' NHS Foundation Trust
2021-2023
St Thomas' Hospital
2022
King's College Hospital NHS Foundation Trust
2019-2022
Royal London Hospital
2021
Bristol Royal Infirmary
2021
NIHR Bristol Cardiovascular Biomedical Research Unit
2021
Abstract Aims Myocardial scar detected by cardiovascular magnetic resonance has been associated with sudden cardiac death in dilated cardiomyopathy (DCM). Certain genetic causes of DCM may cause a malignant arrhythmogenic phenotype. The concepts left ventricular (LV) (ALVC) and are currently ill-defined. We hypothesized that distinctive imaging phenotype defines ALVC. Methods results Eighty-nine patients DCM-associated mutations [desmoplakin (DSP) n = 25, filamin C (FLNC) 7, titin 30, lamin...
Background: Increased concentrations of low density lipoprotein cholesterol (LDL-C), as well small dense LDL-C (sdLDL-C), are considered cardiovascular risk factors.Objective: An assessment the effects ezetimibe and orlistat administration, alone or in combination, on sdLDL-C levels (primary endpoint), anthropometric variables metabolic parameters (secondary endpoints) overweight obese patients [body mass index (BMI) > 28 kg/m2] with hypercholesterolaemia [total 200 mg/dL (5.2...
Presence of heart failure is associated with a poor prognosis in patients coronavirus disease 2019 (COVID-19). The aim the present study was to examine whether first-phase ejection fraction (EF1), measured early systole up time peak aortic velocity, sensitive measure preclinical failure, survival hospitalized COVID-19. A retrospective outcome performed COVID-19 who underwent echocardiography (n=380) at West Branch Union Hospital, Wuhan, China and admitted King's Health Partners South London,...
We investigated the factors influencing triglycerides (TG) reduction during ezetimibe, alone or combined with orlistat, administration. Eighty-six obese hypercholesterolemic subjects were prescribed a low-fat diet and randomized to ezetimibe (E group), orlistat (O both (OE group) for 6 months. Plasma TG apolipoprotein (apo) C-III was significantly greater in combination group compared monotherapy. Multivariate analysis showed that E apoC-III baseline levels independently positively...
Objective: The management of obese hypertensive subjects may require the administration anti-obesity and antihypertensive drugs. Sibutramine use has raised concerns regarding a potential increase in subjects' blood pressure heart rate. primary end-points this study were an evaluation effect sibutramine together with verapamil sustained release/trandolapril combination tablet versus alone on rate patients. Research design/methods: Patients received low-fat low-calorie diet randomly allocated...
Aims: To compare the effects of ezetimibe plus orlistat or rimonabant on anthropometric and lipid parameters in nondiabetic statin-intolerant overweight/obese patients with dyslipidemia. Methods results: Thirty participants received a hypocaloric diet were randomized to open-label combination (10 mg/day) (120 mg, 3 times day meals; ezetimibe/orlistat [EO], n = 15) (20 mg/day; ezetimibe/ [ER], 15). Anthropometric metabolic variables assessed at baseline months posttreatment. Similar...
Although sacubitril/valsartan has recently shown its long-term benefits on morbidity and mortality in symptomatic patients with chronic heart failure reduced ejection fraction (HFrEF), short-term effects diastolic function remain uncertain. We sought to assess 30-day of left ventricular (LV) paremeters determined by speckle tracking tissue Doppler imaging (STI TDI respectively) as well their association functional capacity change evaluated peak oxygen uptake (VO2max) stable HFrEF.A total 35...
Background Despite robust data on the benefits of sacubitril/valsartan (LCZ696) in patients with chronic heart failure reduced ejection fraction (HFrEF), there is no evidence yet prespecified predictive markers its efficacy. Hypothesis The objective this study was to identify potential prognostic factors LCZ696 treatment response. Methods We included 48 symptomatic HFrEF (left ventricular ≤35%) and New York Heart Association (NYHA) class II/III: Group A (N = 23) received (105 ± 30 mg twice...